- MEDICA16
-
- $58.00 / 5mg
-
2026-01-05
- CAS:87272-20-6
- Min. Order:
- Purity: 99.87%
- Supply Ability: 10g
|
| | MEDICA 16 Basic information |
| Product Name: | MEDICA 16 | | Synonyms: | MEDICA 16;3,3,14,14-TETRAMETHYLHEXADECANEDIOIC ACID;3,3,14,14-TETRAMETHYLHEXADECANEDIONIC ACID;Hexadecanedioic acid, 3,3,14,14-tetramethyl-;ACLY,antidiabetogenic,ATP Citrate Lyase,antidiabetic,skeletal,Inhibitor,MEDICA16,ligands,Free Fatty Acid Receptor,MEDICA-16,insulin,FFAR,endogenous,muscle,inhibit;MEDICA16, 10 mM in DMSO | | CAS: | 87272-20-6 | | MF: | C20H38O4 | | MW: | 342.51 | | EINECS: | | | Product Categories: | | | Mol File: | 87272-20-6.mol |  |
| | MEDICA 16 Chemical Properties |
| Melting point | 154-159 °C | | Boiling point | 485.9±18.0 °C(Predicted) | | density | 0.984±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMSO: 28 mg/mL | | form | solid | | pka | 4.51±0.10(Predicted) | | color | white |
| | MEDICA 16 Usage And Synthesis |
| Description | MEDICA 16 is a β,β''-dimethyl hexadecanedioic acid which exhibits hypolipidemic and antidiabetogenic effects in the rat. In animals that were fed a diet which was 0.25% MEDICA 16 by weight, the hypolipidemic effect consisted of a 70-80% decrease in plasma chylomicrons and VLDL-triacylglycerols as well as a 40-60% decrease in plasma VLDL-cholestrol. | | Uses | MEDICA 16 is a β,β'-dimethyl hexadecanedioic acid which exhibits hypolipidemic and antidiabetogenic effects in the rat. In animals that were fed a diet which was 0.25% MEDICA 16 by weight, the hypolipidemic effect consisted of a 70-80% decrease in plasma chylomicrons and VLDL-triacylglycerols as well as a 40-60% decrease in plasma VLDL-cholestrol. | | Uses | MEDICA 16 is a malic enzyme and mitochondrial glycerol-3-phosphate dehydrogenase inducer. | | Definition | ChEBI: MEDICA 16 is an alpha,omega-dicarboxylic acid that is hexadecanedioic acid carrying methyl groups at positions 3 and 14. It is a free fatty acid 1 (FFA1/GPR40) receptor agonist and an ATP citrate lyase inhibitor, and exhibits hypolipidemic and antidiabetogenic properties. It has a role as an antilipemic drug, an EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor, an EC 2.3.3.8 (ATP citrate synthase) inhibitor, a G-protein-coupled receptor agonist and a hypoglycemic agent. | | storage | -20°C | | References | [1] TAKAFUMI HARA. Novel selective ligands for free fatty acid receptors GPR120 and GPR40.[J]. Naunyn-Schmiedeberg’s archives of pharmacology, 2009, 380 3: 247-255. DOI: 10.1007/s00210-009-0425-9
[2] TIMOTHY N. C. WELLS Barbara A S. Redox control of catalysis in ATP-citrate lyase from rat liver[J]. The FEBS journal, 1992, 204 1: 249-255. DOI: 10.1111/j.1432-1033.1992.tb16631.x
[3] L. L. ATKINSON. MEDICA 16 inhibits hepatic acetyl-CoA carboxylase and reduces plasma triacylglycerol levels in insulin-resistant JCR: LA-cp rats.[J]. Diabetes, 2002, 51 5 1: 1548-1555. DOI: 10.2337/diabetes.51.5.1548
[4] J C RUSSELL. Development of insulin resistance in the JCR:LA-cp rat: role of triacylglycerols and effects of MEDICA 16.[J]. Diabetes, 1998, 47 5: 770-778. DOI: 10.2337/diabetes.47.5.770 |
| | MEDICA 16 Preparation Products And Raw materials |
|